Clinical Impact of Telomere Length Testing for Interstitial Lung Disease

David Zhang,Christina M Eckhardt,Claire McGroder,Shannon Benesh,Julie Porcelli,Christopher Depender,Kelsie Bogyo,Joseph Westrich,Amanda Thomas-Wilson,Vaidehi Jobanputra,Christine K Garcia
DOI: https://doi.org/10.1016/j.chest.2024.06.006
IF: 9.6
2024-06-29
Chest
Abstract:Background: Shortened telomere length (TL) is a genomic risk factor for fibrotic interstitial lung disease (ILD), but its role in clinical management is unknown. Research question: What is the clinical impact of TL testing on the management of ILD? Study design and methods: Patients were evaluated in the Columbia University ILD clinic and underwent Clinical Laboratory Improvement Amendments-certified TL testing by flow cytometry and fluorescence in situ hybridization (FlowFISH) as part of clinical treatment. Short TL was defined as below the 10th age-adjusted percentile for either granulocytes or lymphocytes by FlowFISH. Patients were offered genetic counseling and testing if they had short TL or a family history of ILD. FlowFISH TL was compared with research quantitative polymerase chain reaction (qPCR) TL measurement. Results: A total of 108 patients underwent TL testing, including those with clinical features of short telomere syndrome such as familial pulmonary fibrosis (50%) or extrapulmonary manifestations in the patient (25%) or a relative (41%). The overall prevalence of short TL was 46% and was similar across clinical ILD diagnoses. The number of short telomere clinical features was independently associated with detecting short TL (OR, 2.00; 95% CI, 1.27-3.32). TL testing led to clinical treatment changes for 35 patients (32%), most commonly resulting in reduction or avoidance of immunosuppression. Of the patients who underwent genetic testing (n = 34), a positive or candidate diagnostic finding in telomere-related genes was identified in 10 patients (29%). Inclusion of TL testing below the 1st percentile helped reclassify eight of nine variants of uncertain significance into actionable findings. The qPCR test correlated with FlowFISH, but age-adjusted percentile cutoffs may not be equivalent between the two assays. Interpretation: Incorporating TL testing in ILD impacted clinical management and led to the discovery of new actionable genetic variants.
What problem does this paper attempt to address?